Regarding point number 11 (AlphaFold3 vs Vina, Gnina, etc.), see my rebuttal here (I'm the author of Vina): <a href="https://olegtrott.substack.com/p/are-alphafolds-new-results-a-miracle" rel="nofollow">https://olegtrott.substack.com/p/are-alphafolds-new-results-...</a><p>Gnina is Vina with its results re-scored by a NN, so the exact same concerns apply.<p>I'm very optimistic about AI, for the record. It's just that in this particular case, the comparison was flawed. It's the old regurgitation vs generalization confusion: We need a method that generalizes to completely novel drug candidates, but the evaluation was done on a dataset that tends to be repetitive.